Last reviewed · How we verify
DAS181 dry powder, formulation F02 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
DAS181 dry powder, formulation F02 (DAS181 dry powder, formulation F02) — Ansun Biopharma, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DAS181 dry powder, formulation F02 TARGET | DAS181 dry powder, formulation F02 | Ansun Biopharma, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DAS181 dry powder, formulation F02 CI watch — RSS
- DAS181 dry powder, formulation F02 CI watch — Atom
- DAS181 dry powder, formulation F02 CI watch — JSON
- DAS181 dry powder, formulation F02 alone — RSS
Cite this brief
Drug Landscape (2026). DAS181 dry powder, formulation F02 — Competitive Intelligence Brief. https://druglandscape.com/ci/das181-dry-powder-formulation-f02. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab